Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Bristol Myers’ Growth Portfolio generated approximately 57% of revenue in the first nine months of 2026; Opdivo Qvantig reached an annualized revenue run rate above $1.3B. BMY raised its 2026 revenue guidance, while forecasting Eliquis revenue growth of 20–25% despite upcoming loss of exclusivity in Europe; the Legacy Portfolio declined 3% over the nine-month period, with full-year deterioration now expected at 3–5% versus the prior 4–6% forecast. Shares are up 15.2% year to date, but the 2026 EPS consensus fell to $6.46 from $6.91 in the past 30 days, underscoring continued earnings and patent-erosion risks.

Analysis

The key question is whether newer brands add enough incremental economics to outrun legacy erosion—not simply whether their share of revenue rises as older products shrink. The Opdivo Qvantig run rate may partly reflect formulation migration from IV Opdivo, so it is not clean evidence of franchise growth; product-level sales and margin data are needed to separate conversion from expansion. Broader adoption in Camzyos, Reblozyl and Breyanzi is more constructive, but pipeline and label-expansion optionality should not be treated as near-term revenue.

Eliquis creates a two-sided exposure: European exclusivity loss can pressure Bristol Myers and Pfizer, while U.S. growth may cushion the decline. The article does not quantify either the geographic revenue mix or the partners’ respective economics, so the net earnings sensitivity is unverified. Pfizer’s oncology assets and Merck’s Keytruda franchise are potential relative beneficiaries of continued competitive pressure, but the article provides no evidence that this news changes their near-term estimates.

The cautious signal is the divergence between lower 2026 and slightly higher 2027 EPS estimates despite improved revenue guidance. That points to a possible mix, cost, or earnings-conversion issue; revenue growth alone may not support multiple re-rating. Near term, guidance and quarterly product trends matter most; over 6–18 months, generic erosion and Eliquis exclusivity are the structural test. A sharp reversal in new-brand adoption, weaker U.S. Eliquis demand, or further EPS estimate cuts would falsify the offset thesis.

Key Decisions for Investors

• Do not chase Bristol Myers solely on the raised revenue outlook. Treat the setup as neutral until reported growth-brand sales translate into stable or improving earnings estimates.
• Watch the next quarterly disclosure for product-level sales and profitability—especially whether Opdivo Qvantig growth is incremental or mainly a switch from IV Opdivo, and whether Camzyos, Reblozyl and Breyanzi growth broadens.
• Keep Pfizer’s Eliquis exposure on a catalyst watch, not as a standalone short: verify European launch timing, regional sales mix and the partners’ economic split before sizing a position. Continued U.S. growth that offsets the European decline would weaken the downside case.
• A relative-value long Merck versus Bristol Myers is only a conditional watch item, not a current recommendation: require evidence of Bristol Myers EPS stabilization and a clear estimate-revision catalyst first. Further cuts to forward EPS despite brand growth would support the relative underweight; sustained upward revisions would invalidate it.